Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
It is not a drug, food, supplement, or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure, or prevent any disease, or for human or veterinary consumption
Behavior support, like counseling or group programs, provides extra structure and motivation
The peptide is structured with a C20 fatty diacid modification at Lys, enabling once-weekly subcutaneous dosing through albumin binding
Obesity and adipose tissue research Type 2 diabetes and insulin resistance Knee osteoarthritis Obstructive sleep apnea Non-alcoholic steatohepatitis (NASH) Key Findings from the Literature 01Phase 2: 24.2% mean weight loss at 48 weeks at highest dose 02Phase 3 TRIUMPH-4: 28.7% mean weight loss at 68 weeks 03Highest weight loss efficacy of any obesity pharmacotherapy in clinical trials to date 04Glucagon receptor agonism adds hepatic lipolysis absent from GLP-1-only agents 1 Independent third-party lab reports for this peptide
Retatrutide has been investigated in research for its effects on metabolic regulation, appetite pathways, and weight management studies
For best outcomes, retatrutide should be complemented with lifestyle modifications such as nutrition, exercise, and behavioral support in a comprehensive obesity treatment strategy
